Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Nine Endocrine And Metabolic Disease Drug Launches To Look Out For In 2022

Sep 28 2021

• By Alexandra Shimmings

• Source: Alamy

Related Content

Bayer Hopeful Of Sweet Success With KaNDy Buy

Aug 11 2020

Alnylam's Phase III Results For Vutrisiran Are 'Foundation' For Amyloidosis Expansion

Jan 07 2021

Agios’ Mitapivat Shows Improvement In Regularly Transfused PKD Patients

Jan 27 2021

Lilly's Tirzepatide Shows Up Novo's Ozempic In Head-To-Head Diabetes Trial

Mar 04 2021

Butterfly Skin Therapy Pipeline Primed For Transformation

Jun 03 2021

Novo Nordisk’s GLP-1 Franchise Buoyed By SUSTAIN FORTE data

Jun 29 2021

Astellas Eyes Doubling Market Cap On Core, Focus Assets

Jun 01 2021

AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840

Aug 26 2021

Lilly Aims For Earlier Treatment With Novel Diabetes Drugs

Jul 07 2021

Related Companies

Eli Lilly and Company

Novo Nordisk A/S

Astellas Pharma, Inc.

Castle Creek Biosciences, Inc.

Krystal Biotech, Inc.

Alnylam Pharmaceuticals Inc.

Akcea Therapeutics, Inc.

Pfizer Inc.

Sanofi

Agios Pharmaceuticals, Inc.

AstraZeneca PLC

Alexion Pharmaceuticals Inc.

Vivet Therapeutics

Ionis Pharmaceuticals, Inc.

Additional Topics

Approvals Companies Research & Development Commercial Gene Therapy Metabolic Disorders Gynecology & Urology BioPharmaceutical

More from New Products

More from Scrip

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window